Zobrazeno 1 - 10
of 17
pro vyhledávání: '"S S, Koca"'
Autor:
C. Akleylek, S. Akar, H. Cinakli, R. Piskin Sagir, B. N. Coşkun, A. Karakas, H. Apaydin, R. C. Kardaş, O. Ozdemir Isik, S. Hakbilen, B. Okyar, O. Sosyal, S. S. Koca, Y. Pehlivan, E. Dalkiliç, G. Can, İ. Sari, M. Birlik, F. Onen, S. Erten, M. A. Ozturk, A. Yazici, A. Cefle, S. Yilmaz, G. Yildirim Cetin, N. Akkoc, N. Yilmaz
Publikováno v:
Annals of the Rheumatic Diseases. 81:1507-1508
BackgroundSecukinumab (SEC), a human anti-IL-17A monoclonal antibody, has similar treatment response rates to tumor necrosis factor (TNF) inhibitors in patients with axial spondyloarthritis (SpA). However, the efficacy of SEC on anterior uveitis (AU)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46a0dee62c20b4b6901f60b04b99f15b
https://doi.org/10.1136/annrheumdis-2022-eular.2248
https://doi.org/10.1136/annrheumdis-2022-eular.2248
Autor:
E. Durak Ediboglu, U. Kalyoncu, D. Solmaz, T. Kaşifoğlu, E. Tekgoz, C. Bes, A. Erden, B. Yağiz, N. A. Kanitez, A. İ. Ertenli, B. N. Coşkun, R. Mercan, S. Kiraz, V. Yazisiz, O. Küçükşahin, A. Ateş, R. Yilmaz, Y. Pehlivan, H. Emmungil, N. S. Yasar Bilge, G. Kimyon, E. D. Ersözlü, E. Dalkiliç, S. S. Koca, S. Akar
Publikováno v:
Annals of the Rheumatic Diseases. 81:812.2-813
BackgroundAxial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints, spine and peripheral joints. In addition to spinal and peripheral manifestations, root joints (hip or sholder) involvement may also dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a65de3a71d7968cda261035d7f6e630
https://doi.org/10.1136/annrheumdis-2022-eular.4962
https://doi.org/10.1136/annrheumdis-2022-eular.4962
Autor:
R. Mercan, M. E. Tezcan, B. Yağiz, A. Ateş, O. Küçükşahin, N. S. Yasar Bilge, N. A. Kanitez, E. Gönüllü, S. Yilmaz, D. Ersözlü, D. Solmaz, T. Kaşifoğlu, B. N. Coşkun, S. S. Koca, E. Bilgin, V. Yazisiz, E. Dalkiliç, R. Yilmaz, G. Kimyon, G. Ayan, A. Erden, C. Bes, H. Emmungil, Y. Pehlivan, A. İ. Ertenli, S. Kiraz, U. Kalyoncu
Publikováno v:
Annals of the Rheumatic Diseases. 81:1509.2-1510
BackgroundBiological therapies are the main treatment options for patients with active spondyloarthropathy (SpA) who do not respond to nonsteroidal anti-inflammatory drugs or conventional synthetic disease-modifying drugs. Kidney diseases are not a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5d963aadb9e5b952dfa8d3de10f6f03
https://doi.org/10.1136/annrheumdis-2022-eular.3042
https://doi.org/10.1136/annrheumdis-2022-eular.3042
Autor:
E. Gönüllü, U. Kalyoncu, B. Yağiz, A. Ateş, O. Küçükşahin, Ş. Yaşar Bilge, N. A. Kanitez, M. Çinar, D. Ersözlü, R. Mercan, S. Akar, T. Kaşifoğlu, B. N. Coşkun, S. S. Koca, E. Bilgin, V. Yazisiz, E. Dalkiliç, R. Yilmaz, G. Kimyon, S. M. Türk, A. Erden, C. Bes, H. Emmungil, Y. Pehlivan, A. İ. Ertenli, S. Kiraz
Publikováno v:
Annals of the Rheumatic Diseases. 81:1304.1-1304
BackgroundInflammatory musculoskeletal diseases are frequent in the elderly population, and this number is expected to increase significantly near future. The exclusion of older adults from the studies due to their age and comorbidities causes insuff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0e6f0bb08f772a421dc038599670b42
https://doi.org/10.1136/annrheumdis-2022-eular.2721
https://doi.org/10.1136/annrheumdis-2022-eular.2721
Autor:
D. Ersözlü, M. Ekici, B. N. Coşkun, S. Ö. Badak, E. Bilgin, U. Kalyoncu, B. Yağiz, Y. Pehlivan, O. Küçükşahin, A. Erden, D. Solmaz, P. Atagündüz, G. Kimyon, C. Bes, S. Colak, R. Mercan, T. Kaşifoğlu, H. Emmungil, N. A. Kanitez, A. Ateş, S. S. Koca, S. Kiraz, A. İ. Ertenli
Publikováno v:
Annals of the Rheumatic Diseases. 81:919.3-920
BackgroundRecent epidemiological data on HBV and HCV in Turkey revealed that the seroprevalence rates of hepatitis B surface antigen and antibody against HCV were 4% and 1%, respectively, and seropositivity rates for hepatitis B surface antibody and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd59ccb1387802a10928406469812920
https://doi.org/10.1136/annrheumdis-2022-eular.3064
https://doi.org/10.1136/annrheumdis-2022-eular.3064
Autor:
T. Demirci Yildirim, C. Akleylek, H. Cinakli, D. Yildirim, S. Hakbilen, B. N. Coşkun, B. Okyar, O. Ozdemir Isik, R. Piskin Sagir, H. Apaydin, S. Gulle, Y. Erez, T. Yuce Inel, N. Yilmaz, S. Akar, A. Tufan, S. Yilmaz, Y. Pehlivan, G. Yildirim Cetin, A. Cefle, S. S. Koca, S. Erten, A. Yazici, E. Dalkiliç, G. Can, İ. Sari, M. Birlik, F. Onen
Publikováno v:
Annals of the Rheumatic Diseases. 81:1662.3-1663
BackgroundConsidering the concerns regarding COVID-19 vaccine safety among patients with rheumatic diseases due to a lack of data, an urgent need for studies evaluating safety profiles of vaccines emerged.ObjectivesVaccination against the coronavirus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66be93fcff056f6a50cfa3d3272691a6
https://doi.org/10.1136/annrheumdis-2022-eular.390
https://doi.org/10.1136/annrheumdis-2022-eular.390
Autor:
N. Inanc, K. Abacar, M. A. Ozturk, A. Tufan, H. Karadeniz, İ. Sari, G. Can, Y. Erez, Y. Pehlivan, E. Dalkiliç, T. Ocak, A. Cefle, A. Yazici, A. Senel, S. Akar, E. Durak Ediboglu, S. S. Koca, R. Piskin Sagir, S. Yilmaz, S. Gulcemal, Ö. Soysal Gündüz, C. S. Başibüyük, S. Alkan, T. Y. Cesur, F. Onen
Publikováno v:
Annals of the Rheumatic Diseases. 81:1338.1-1338
BackgroundCombination of MTX with a bDMARDs or tsDMARDs is considered the most effective treatment regimen currently available for patients with RA who have failed to respond to conventional DMARDs. However, approximately 30% of patients receive bDMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38e24dce53ad355056d1e4f2b1add31c
https://doi.org/10.1136/annrheumdis-2022-eular.5102
https://doi.org/10.1136/annrheumdis-2022-eular.5102
Publikováno v:
Clinical and experimental dermatology. 37(1)
T lymphocytes induce the transformation of fibroblasts into myofibroblasts, the main mediators of fibrogenesis. The inosine 5'-monophosphate dehydrogenase inhibitor mycophenolate mofetil (MMF) and the anti-CD25 monoclonal antibody daclizumab (DCZ) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e88458a448d771b15b81043f1bd25fca
https://pubmed.ncbi.nlm.nih.gov/22182434
https://pubmed.ncbi.nlm.nih.gov/22182434
Autor:
Başımoğlu Koca Y; Adnan Menderes University, Faculty of Science and Art, Department of Biology , 09010 Aydin , Turkey., Koca S
Publikováno v:
Biotechnic & histochemistry : official publication of the Biological Stain Commission [Biotech Histochem] 2014 Jan; Vol. 89 (1), pp. 41-52. Date of Electronic Publication: 2013 Aug 19.
Autor:
Sahinler I; Istanbul University, Cerrahpasa Medical Faculty, Department of Radiation Oncology, and Italian Hospital, Istanbul, Turkey. drismet@istanbul.edu.tr, Atalar B, Tecer GM, Calay Z, Koca S, Atkovar G, Okkan S
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology [J BUON] 2010 Jul-Sep; Vol. 15 (3), pp. 480-8.